Clinical Pharmacists´ Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review

Moamen Abdelfadil Ismail[1], Maged Mohammed M Alharbi[2], Turki Hamed Naffaa Almusihli[3], Turki hassan suliman alqattan[4], Fahad Shaag Ibraheem Alotibi[5], Amnah A Asiri[6]

Abstract

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder with significant complications that affect quality of life and burden healthcare systems. Despite advances in diabetes management, many patients fail to achieve optimal therapeutic goals, emphasizing the need for innovative, multidisciplinary care approaches. Clinical pharmacists have emerged as key contributors to improving T2DM outcomes.This systematic review assessed the impact of pharmacist-led interventions on clinical, humanistic, and economic outcomes in T2DM management. Two databases, PubMed and the Cochrane Central Register of Controlled Trials, were searched for randomized controlled trials comparing pharmacist-led interventions with standard care. Studies reporting outcomes such as HbA1c, blood pressure, lipid profiles, BMI, medication adherence, health-related quality of life (HRQoL), and economic data were included. Data were synthesized and analyzed for changes from baseline to follow-up.A total of 41 studies involving 6,529 participants were included. Pharmacist-led interventions significantly improved HbA1c (reductions ranging from -0.05% to -2.1%), blood glucose, blood pressure, lipid profiles, and BMI. Improvements in medication adherence were observed in 14 studies, with significant gains in 5. Economic analyses indicated cost-effectiveness, with interventions reducing medical costs and improving quality-adjusted life years (QALYs). However, limited studies reported significant changes in HRQoL.Pharmacist-led interventions demonstrated substantial benefits in improving metabolic control, reducing cardiovascular risks, and enhancing medication adherence in T2DM management. The findings advocate for integrating pharmacists into multidisciplinary teams to optimize diabetes care. Further research on humanistic and economic outcomes is essential to support policy decisions.

Keywords: *Clinical Pharmacists, Type 2 Diabetes Mellitus, Metabolic Disorder.*

Introduction

Type 2 diabetes mellitus (T2DM) is a multifaceted metabolic disorder defined by significant pathophysiological changes, including impaired insulin sensitivity and a gradual decline in insulin production, which together lead to elevated blood sugar levels (1,2). This condition arises from a combination of genetic, epigenetic, and behavioral factors, all of which interact within a given sociocultural context (1). Poorly managed glycemic levels contribute to diabetes-related complications, such as microvascular and macrovascular damage, which in turn increase morbidity, mortality, and diminish overall quality of life (3,4). The global economic impact of diabetes and its complications poses a serious concern for healthcare systems worldwide.

Research indicates that despite advances in blood glucose monitoring, management of cardiovascular risk factors (e.g., blood pressure and lipid levels), and the availability of numerous treatment options, many individuals with T2DM fail to meet recommended therapeutic goals (5,6-7). These less-than-optimal results may be attributed to ineffective healthcare interventions or challenges related to patient adherence and engagement (8,9).

To improve outcomes and support better management of T2DM, healthcare systems need to adopt innovative care models that emphasize collaboration, proactive strategies, and integrated teamwork, with

---

[1] Internal Medicine consultant, King Abdulaziz Specialist Hospital - Lecturer of Internal Medicine, Faculty of Medicine, Helwan University, Email: moamen.fadil83@gmail.com
[2] Technician-Pharmacy, Madinah Cardiac Center.
[3] Technician-Pharmacy, Madinah Cardiac Center.
[4] Technician-Pharmacy, Madinah Cardiac Center
[5] Pharmacy Technician, Al-Dawadmi General Hospital
[6] pharmacist, Abha Maternity and Children Hospital

active participation from patients (1,10,11-12). While some systematic reviews have explored this subject, they often lack a thorough evaluation of economic implications (13,14,15,16-17).

This study aims to systematically examine the impact of clinical pharmacist-led interventions on T2DM management by assessing clinical, humanistic, and economic outcomes, focusing exclusively on randomized controlled trials conducted in healthcare settings such as hospitals or ambulatory care centers.

Methods

Two online databases (PubMed and the Cochrane Central Register of Controlled Trials) were searched from their inception dates until September 13, 2017, with an update conducted on June 30, 2024.

The search strategy used for PubMed was adapted to formulate the search approach for the Cochrane Central Register of Controlled Trials. Search terms included a combination of medical subject headings (MeSH) and keywords, applied using Boolean operators.

Studies were deemed eligible if they fulfilled the following criteria: (1) randomized controlled trials comparing the effectiveness of pharmacist-led interventions for individuals with T2DM against standard care; (2) conducted in inpatient or outpatient settings (e.g., clinics or healthcare centers) and reported outcomes such as glycosylated hemoglobin (HbA1c), fasting or postprandial blood glucose, blood pressure, lipid profile [total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides], body mass index (BMI), 10-year coronary heart disease (CHD) risk, medication adherence, health-related quality of life (HRQoL), and economic analyses; (3) published in English, French, Spanish, or Portuguese; and (4) without restrictions on the publication year.

Study Selection

Two independent reviewers evaluated the titles and abstracts retrieved from the databases based on the predefined inclusion criteria. Articles identified as potentially relevant underwent full-text review by two reviewers to confirm their eligibility for inclusion. The process adhered to the PRISMA guidelines for systematic reviews, as recommended (18). Disagreements were resolved through discussion between the reviewers.

Data Extraction and Synthesis

One reviewer conducted data extraction from the eligible studies, and a second reviewer independently verified the extracted information. Results for each outcome were presented as changes from baseline to the final follow-up in both the intervention and control groups. If not explicitly reported, the difference in change between the groups was calculated (change from baseline in the intervention group minus change from baseline in the control group). Units of measurement for clinical outcomes were standardized where necessary to facilitate comparison.

Results

The database search identified a total of 748 citations. After screening the titles and abstracts, 84 citations were identified as potentially meeting the inclusion criteria. Following a detailed review of the full texts, 41 studies met the inclusion criteria and were included in this systematic review (20–73). Furthermore, three study reports found within the search results provided additional data relevant to the outcomes from some of the included studies (59–61).

The 41 included studies were conducted across various regions and settings, such as hospitals, primary healthcare centers, and outpatient clinics. These studies involved a combined total of 6,529 participants globally, with follow-up periods ranging from 45 days to 24 months.

All included studies observed reductions in mean HbA1c values within the intervention groups compared to baseline, with statistically significant reductions reported in 18 studies (43.9%) (23, 25, 27–29, 35, 37–39, 41, 42, 45, 50, 52, 56, 57, 72, 73). The change in HbA1c between intervention and control groups ranged from -0.05% to -2.1%. Regarding blood glucose, 24 studies reported this parameter as an outcome, with 7 (29.2%) demonstrating statistically significant reductions (39, 40, 42, 45, 46, 56, 72). Differences in blood glucose changes between groups ranged from -7.74 mg/dL to -76.32 mg/dL.

Changes in systolic blood pressure (SBP) were assessed in 22 studies, with significant differences between intervention and control groups reported in 8 studies (36.4%) (31, 35, 39, 40, 41, 45, 50, 72). The difference in SBP change ranged from +3.45 mmHg to -10.6 mmHg. For diastolic blood pressure (DBP), data were reported in 16 studies, with only 4 studies (25%) showing significant differences (39, 41, 53, 72). The difference in DBP change between groups ranged from +1.32 mmHg to -9.1 mmHg.

Outcomes related to lipid profiles were variable. Fifteen studies measured total cholesterol, but only 5 (33.3%) reported statistically significant differences (39, 41, 45, 72, 73). Changes in total cholesterol levels ranged from +10.06 mg/dL to -32.48 mg/dL. For LDL cholesterol, 23 studies reported data, with 9 (39.1%) showing significant differences (27, 29, 35, 39, 40, 45, 57, 72, 73), with changes ranging from +2.1 mg/dL to -27 mg/dL. HDL cholesterol was reported in 16 studies, with only 2 (12.5%) reporting significant differences (45, 72). Differences in HDL levels ranged from -5.8 mg/dL to +11 mg/dL. Lastly, among the 18 studies that reported triglyceride levels, 4 (22.2%) observed significant differences (39, 40, 45, 73), with changes ranging from +21.26 mg/dL to -62.0 mg/dL.

BMI outcomes were described in 18 studies, with 12 studies showing greater reductions in the intervention group. However, only 2 studies (11.1%) reported statistically significant differences in BMI changes between groups (41, 72). Changes in BMI ranged from +0.6 kg/m² to -1.94 kg/m².

Predicted 10-year CHD risk was assessed in 6 studies using various methods, with significant differences reported in 3 studies (50%) (27, 53, 72). Among studies using the Framingham prediction method, the difference in CHD risk reduction between groups ranged from -3.0% to -12.0%.

Medication adherence was assessed in 22 studies, with improvements noted in the intervention groups in 14 studies. However, only 5 studies (22.7%) reported significant improvements (23, 25, 27, 35, 72). HRQoL was evaluated in 13 studies, but significant differences between groups were observed in only 2 studies (15.4%) (25, 72).

Economic analyses were conducted in 8 studies, with only 3 providing significant p-values (27, 59, 61). One study found that pharmacist-led interventions led to an incremental cost of USD 69 and an incremental effect of 0.12 QALY gained, with a cost-effectiveness ratio of USD 571 per QALY (59). Another study estimated potential cost savings of USD 5,086.3 per patient due to CHD risk reduction (27). A third study observed a 6% decrease in medical costs for the intervention group compared to a 13% increase in the control group (58).

Discussion

This systematic review synthesized evidence from randomized controlled trials examining the impact of various interventions led by clinical pharmacists on outcomes related to the management of T2DM. Unlike previous reviews, this work not only highlights the positive influence of clinical pharmacists on metabolic control in T2DM but also incorporates their role in economic and humanistic outcomes (13, 14, 15–16, 62). The role of clinical pharmacists in delivering targeted interventions to patients often remains underappreciated compared to other healthcare professionals. This review emphasizes the substantial capacity of pharmacists to actively participate in multidisciplinary healthcare teams, delivering effective interventions such as patient education, medication reviews, and case management with continuous follow-up. Interventions frequently included medication optimization, patient education, and coordination with other healthcare providers. The diversity of these interventions reflects variations in pharmacist roles and integration into healthcare systems globally, particularly regarding their autonomy to make medication

adjustments. Evidence from the studies reviewed consistently underscores the beneficial impact of pharmacists on T2DM care. Regular follow-up by pharmacists could enhance the effectiveness of these interventions even further (63).

Improvements in HbA1c, blood glucose, blood pressure, lipid profiles, and BMI were consistently reported in intervention groups across nearly all included studies.

The results align with findings from other systematic reviews on this topic. A review by Wubben et al. reported significant improvements in mean HbA1c levels within intervention groups, with differences in HbA1c changes ranging from +0.2% to -2.1% between intervention and control groups (16). Improvements in glycemic control are crucial, as they are associated with reduced risks of diabetes-related complications, including lower risks of stroke (12%), myocardial infarction (14%), and heart failure (16%) (64). Although fasting or non-fasting blood glucose levels were reported in some studies, they hold less clinical relevance than HbA1c levels, and few studies demonstrated statistically significant differences.

This review also found reductions in blood pressure, lipid profiles, and BMI, supporting evidence from other studies (15, 16–17, 62). For example, Santschi et al. found that pharmacist-led interventions significantly reduced systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, and BMI, although HDL cholesterol remained unaffected (15). Similarly, Wubben et al. observed decreases in blood pressure, low-density lipoprotein cholesterol, and triglycerides in intervention groups, though differences between groups were not always statistically significant (16).

Although studies assessing the effect of pharmacist interventions on coronary heart disease (CHD) risk are limited, available evidence suggests these interventions can improve CHD risk profiles. CHD risk reduction is often linked to improved clinical outcomes, such as lower HbA1c, systolic blood pressure, and cholesterol levels (65, 66–67). Additionally, pharmacist interventions positively influenced medication adherence in most studies, despite the reliance on self-reported adherence measures, which could overestimate adherence rates. Nevertheless, improved adherence can contribute to better clinical outcomes, as demonstrated in multiple studies (68, 69).

Conversely, improvements in health-related quality of life (HRQoL) were less frequently observed. This may stem from the limited sensitivity of current tools to detect subtle changes in HRQoL. The lack of a standardized instrument specifically designed to assess the impact of pharmacist interventions on patient quality of life may further explain this outcome (70).

While pharmacist interventions have shown promise in terms of cost-effectiveness, the limited number of studies performing economic analyses restricts the generalizability of these findings. Economic evaluations are crucial for informing policymakers about the value of integrating pharmacists into T2DM care, especially considering the financial constraints faced by healthcare systems. Future studies should adopt a holistic approach, examining clinical, humanistic, and economic outcomes using the ECHO framework (71).

Limitations

Several limitations must be acknowledged. While randomized controlled trials are considered the gold standard, some included studies exhibited methodological limitations as identified through the Cochrane risk of bias tool. Factors such as unclear random sequence generation, allocation concealment, and outcome assessment blinding were commonly rated as "unclear" due to insufficient reporting. Additionally, the heterogeneity of pharmacist interventions in these studies complicates the identification of the most effective strategies. Educational interventions and medication management emerged as promising approaches for improving T2DM outcomes, but further research is needed to confirm these findings.

Conclusions

The evidence presented in this review reinforces the significant role pharmacists play in managing T2DM. Patients with this chronic condition often have additional comorbidities requiring complex therapeutic regimens. By ensuring proper medication use, educating patients, and enhancing adherence, pharmacists are integral to achieving therapeutic goals. The findings from this review demonstrate that pharmacist interventions improve metabolic control, reduce cardiovascular risk factors, enhance medication adherence, and, to some extent, improve HRQoL in T2DM patients. These results advocate for the inclusion of pharmacists as essential members of multidisciplinary healthcare teams and highlight the need for their expanded role in healthcare systems globally.

References

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98. https://doi.org/10.1038/nrendo.2017.151 [Links]

American Diabetes Association. Standards of Medical Care in Diabetes-2017 Abridged for Primary Care Providers. Clin Diabetes. 2017;35(1):5-26. https://doi.org/10.2337/cd16-0067 [Links]

Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: The associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8:18. Published 2010 Feb 4. https://doi.org/10.1186/1477-7525-8-18 [Links]

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. https://doi.org/10.1136/bmj.321.7258.405 [Links]

Jenssen TG, Tonstad S, Claudi T, Midthjell K, Cooper J. The gap between guidelines and practice in the treatment of type 2 diabetes A nationwide survey in Norway. Diabetes Res Clin Pract. 2008;80(2):314-320. https://doi.org/10.1016/j.diabres.2007.12.025 [Links]

Kemp TM, Barr EL, Zimmet PZ, Cameron AJ, Welborn TA, Colagiuri S, Phillips P, Shaw JE. Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes: the 1999-2000 AusDiab. Diabetes Care. 2005;28(6):1490-1492. https://doi.org/10.2337/diacare.28.6.1490 [Links]

Orozco-Beltrán D, Gil-Guillen VF, Quirce F, Navarro-Perez J, Pineda M, Gomez-de-la-Cámara A, Pita S, Diez-Espino J, Mateos J, Merino J, Serrano-Rios M; Collaborative Diabetes Study Investigators. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract. 2007;61(6):909-915. https://doi.org/10.1111/j.1742-1241.2007.01367.x [Links]

Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract. 2011;93(1):1-9. https://doi.org/10.1016/j.diabres.2011.02.002 [Links]

Debussche X. Is adherence a relevant issue in the self-management education of diabetes? A mixed narrative review. Diabetes Metab Syndr Obes. 2014;7:357-367. https://doi.org/10.2147/dmso.s36369 [Links]

American College of Clinical Pharmacy, Hume AL, Kirwin J, Bieber HL, Couchenour RL, Hall DL, Kennedy AK, LaPointe NM, Burkhardt CD, Schilli K, Seaton T, Trujillo J, Wiggins B. Improving care transitions: current practice and future opportunities for pharmacists. Pharmacotherapy. 2012;32(11):e326-e337. https://doi.org/10.1002/phar.1215 [Links]

Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533-543. [Links]

Nichols-English GJ, Provost M, Koompalum D, Chen H, Athar M. Strategies for pharmacists in the implementation of diabetes mellitus management programs - new roles in primary and collaborative care. Disease management & health outcomes 2002;12(9):783-803. https://doi.org/10.2165/00115677-200210120-00005 [Links]

Antoine SL, Pieper D, Mathes T, Eikermann M. Improving the adherence of type 2 diabetes mellitus patients with pharmacy care: a systematic review of randomized controlled trials. BMC Endocr Disord. 2014;14:53. https://doi.org/10.1186/1472-6823-14-53 [Links]

Omran D, Guirguis LM, Simpson SH. Systematic review of pharmacist interventions to improve adherence to oral antidiabetic medications in people with type 2 diabetes Canadian journal of diabetes 2012;36(5):292-299. https://doi.org/10.1016/j.jcjd.2012.07.002 [Links]

Santschi V, Chiolero A, Paradis G, Colosimo AL, Burnand B. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2012;35(12):2706-2717. https://doi.org/10.2337/dc12-0369 [Links]

Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28(4):421-436. https://doi.org/10.1592/phco.28.4.421 [Links]

Fazel MT, Bagalagel A, Lee JK, Martin JR, Slack MK. Impact of Diabetes Care by Pharmacists as Part of Health Care Team in Ambulatory Settings: A Systematic Review and Meta-analysis. Ann Pharmacother. 2017;51(10):890-907. https://doi.org/10.1177/1060028017711454 [Links]

Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-W64. https://doi.org/10.7326/0003-4819-151-4-200908180-00135 [Links]

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928 [Links]

Adams RP, Barton G, Bhattacharya D, Grassby PF, Holland R, Howe A, Norris N, Shepstone L, Wright DJ. Supervised pharmacy student-led medication review in primary care for patients with type 2 diabetes: a randomised controlled pilot study. BMJ Open. 2015;5(11):e009246. https://doi.org/10.1136/bmjopen-2015-009246 [Links]

Pimazoni-Netto A, Zanella MT. Diabetes guidelines may delay timely adjustments during treatment and might contribute to clinical inertia. Diabetes Technol Ther. 2014;16(11):768-770. https://doi.org/10.1089/dia.2014.0092 [Links]

Adibe MO, Ukwe CV, Aguwa CN. The Impact of Pharmaceutical Care Intervention on the Quality of Life of Nigerian Patients Receiving Treatment for Type 2 Diabetes. Value Health Reg Issues. 2013;2(2):240-247. https://doi.org/10.1016/j.vhri.2013.06.007 [Links]

Aguiar PM, da Silva CHP, Chiann C, Dórea EL, Lyra DP Jr, Storpirtis S. Pharmacist-physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: results from a randomized controlled trial. J Eval Clin Pract. 2018;24(1):22-30. https://doi.org/10.1111/jep.12606 [Links]

Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. Br J Clin Pharmacol. 2009;67(5):547-557. https://doi.org/10.1111/j.1365-2125.2009.03391.x [Links]

Butt M, Mhd Ali A, Bakry MM, Mustafa N. Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: A randomised controlled study. Saudi Pharm J. 2016;24(1):40-48. https://doi.org/10.1016/j.jsps.2015.02.023 [Links]

Cani CG, Lopes Lda S, Queiroz M, Nery M. Improvement in medication adherence and self-management of diabetes with a clinical pharmacy program: a randomized controlled trial in patients with type 2 diabetes undergoing insulin therapy at a teaching hospital. Clinics (Sao Paulo). 2015;70(2):102-106. https://doi.org/10.6061/clinics/2015(02)06 [Links]

Chan CW, Siu SC, Wong CK, Lee VW. A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes. J Cardiovasc Pharmacol Ther. 2012;17(1):57-64. https://doi.org/10.1177/1074248410396216 [Links]

Chen JH, Ou HT, Lin TC, Lai EC, Kao YH. Pharmaceutical care of elderly patients with poorly controlled type 2 diabetes mellitus: a randomized controlled trial. Int J Clin Pharm. 2016;38(1):88-95. https://doi.org/10.1007/s11096-015-0210-4 [Links]

Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11(4):253-260. [Links]

Chung WW, Chua SS, Lai PS, Chan SP. Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes. Patient Prefer Adherence. 2014;8:1185-1194. https://doi.org/10.2147/ppa.s66619 [Links]

Cohen LB, Taveira TH, Khatana SA, Dooley AG, Pirraglia PA, Wu WC. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011;37(6):801-812. https://doi.org/10.1177/0145721711423980 [Links]

Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Effect of pharmacist-led patient education on glycemic control of type 2 diabetics: a randomized controlled trial. J Res Med Sci. 2011;16(1):43-49. [Links]

George A, Jewel V, Manohar M, Kumar S, Muneerudeen J. Impact of patient counselling on knowledge, attitude, practices of patients with type 2 diabetes mellitus at a tertiary care teaching hospital. Asian J Pharm Clin Res. 2017;10(5):17637. http://doi.org/10.22159/ajpcr.2017.v10i5.17637 [Links]

Ghosh S, Rajvanshi A, Kishun S. Assessment the influence of patient counseling on quality of life in type-II diabetes mellitus patients. Int J Pharma Bio Sci. 2010;3:6. [Links]

Goruntla N, Mallela V, Nayakanti D. Impact of Pharmacist-directed Counseling and Message Reminder Services on Medication Adherence and Clinical Outcomes in Type 2 Diabetes Mellitus. J Pharm Bioallied Sci. 2019;11(1):69-76. https://doi.org/10.4103/jpbs.jpbs_211_18 [Links]

Grant RW, Devita NG, Singer DE, Meigs JB. Improving adherence and reducing medication discrepancies in patients with diabetes. Ann Pharmacother. 2003;37(7-8):962-969. https://doi.org/10.1345/aph.1c452 [Links]

Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30(3):238-243. https://doi.org/10.1177/106002809603000305 [Links]

Jacobs M, Sherry PS, Taylor LM, Amato M, Tataronis GR, Cushing G. Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study. J Am Pharm Assoc (2003). 2012;52(5):613-621. https://doi.org/10.1331/japha.2012.10183 [Links]

Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. J Manag Care Pharm. 2012;18(7):516-526. https://doi.org/10.18553/jmcp.2012.18.7.516 [Links]

Javaid Z, Imtiaz U, Khalid I, Saeed H, Khan RQ, Islam M, Saleem Z, Sohail MF, Danish Z, Batool F, Anwer N. A randomized control trial of primary care-based management of type 2 diabetes by a pharmacist in Pakistan. BMC Health Serv Res. 2019;19(1):409. Published 2019 Jun 24. https://doi.org/10.1186/s12913-019-4274-z [Links]

Korcegez EI, Sancar M, Demirkan K. Effect of a Pharmacist-Led Program on Improving Outcomes in Patients with Type 2 Diabetes Mellitus from Northern Cyprus: A Randomized Controlled Trial. J Manag Care Spec Pharm. 2017;23(5):573-582. https://doi.org/10.18553/jmcp.2017.23.5.573 [Links]

Lim PC, Lim K, Embee ZC, Hassali MA, Thiagarajan A, Khan TM. Study investigating the impact of pharmacist involvement on the outcomes of diabetes medication therapy adherence program Malaysia. Pak J Pharm Sci. 2016;29(2):595-601. [Links]

Mahwi T, Obied K. Role of the pharmaceutical care in the management of patients with type 2 diabetes mellitus. Int J Pharm Sci Res. 2013;4(4): 1363-1369. http://doi.org/10.13040/IJPSR.0975-8232.4(4).1363-69 [Links]

Maidana GM, Mastroianni PC, Vera Z, Samaniego L, Acosta P, Lugo GB. Impact of pharmaceutical care in clinical outcomes and quality of life of patients with type 2 diabetes mellitus Pharm Care Esp 2016;18(3):107-121. [Links]

Mourão AO, Ferreira WR, Martins MA, Reis AM, Carrillo MR, Guimarães AG, Ev LS. Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial. Int J Clin Pharm. 2013;35(1):79-86. https://doi.org/10.1007/s11096-012-9710-7 [Links]

Nascimento T, Braz N, Gomes E, Fernandez-Arche A, De La Puerta R. Self-care Improvement After a Pharmaceutical Intervention in Elderly Type 2 Diabetic Patients. Curr Diabetes Rev. 2015;12(2):120-128. https://doi.org/10.2174/1573399811666150722130232 [Links]

Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005;39(3):433-440. https://doi.org/10.1345/aph.1e438 [Links]

Plaster CP, Melo DT, Boldt V, Cassaro KO, Lessa FC, Boëchat GA, Bissoli NS, Andrade TU. Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up. Braz J Pharm Sci. 2012;48(3):435-446. https://doi.org/10.1590/S1984-82502012000300010 [Links]

Ramanath K, Santhosh Y. Impact of clinical pharmacist provided patient education on QOL outcome in type II diabetes mellitus in rural population. Asian J Pharm Clin Res. 2011;4(4):15-20. [Links]

Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm. 2006;63(21):2116-2122. https://doi.org/10.2146/ajhp060040 [Links]

Shao H, Chen G, Zhu C, Chen Y, Liu Y, He Y, Jin H. Effect of pharmaceutical care on clinical outcomes of outpatients with type 2 diabetes mellitus. Patient Prefer Adherence. 2017;11:897-903. https://doi.org/10.2147/ppa.s92533 [Links]

Siaw MYL, Ko Y, Malone DC, Tsou KYK, Lew YJ, Foo D, Tan E, Chan SC, Chia A, Sinaram SS, Goh KC, Lee JY. Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. J Clin Pharm Ther. 2017;42(4):475-482. https://doi.org/10.1111/jcpt.12536 [Links]

Simpson SH, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, Spooner R, Johnson JA. Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2011;34(1):20-26. https://doi.org/10.2337/dc10-1294 [Links]

Sriram S, Chack LE, Ramasamy R, Ghasemi A, Ravi TK, Sabzghabaee AM. Impact of pharmaceutical care on quality of life in patients with type 2 diabetes mellitus. J Res Med Sci. 2011;16 Suppl 1(Suppl1): S412-S418. [Links]

Suppapitiporn S, Chindavijak B, Onsanit S. Effect of diabetes drug counseling by pharmacist, diabetic disease booklet and special medication containers on glycemic control of type 2 diabetes mellitus: a randomized controlled trial. J Med Assoc Thai. 2005;88 Suppl 4: S134-S141. [Links]

Wishah RA, Al-Khawaldeh OA, Albsoul AM. Impact of pharmaceutical care interventions on glycemic control and other health-related clinical outcomes in patients with type 2 diabetes: Randomized controlled trial. Diabetes Metab Syndr. 2015;9(4):271-276. https://doi.org/10.1016/j.dsx.2014.09.001 [Links]

Withidpanyawong U, Lerkiatbundit S, Saengcharoen W. Family-based intervention by pharmacists for type 2 diabetes: A randomised controlled trial. Patient Educ Couns. 2019;102(1):85-92. https://doi.org/10.1016/j.pec.2018.08.015 [Links]

Wu WC, Taveira TH, Jeffery S, Jiang L, Tokuda L, Musial J, Cohen LB, Uhrle F. Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial. PLoS One. 2018;13(4):e0195898. https://doi.org/10.1371/journal.pone.0195898 [Links]

Adibe MO, Aguwa CN, Ukwe CV. Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes. Value Health Reg Issues. 2013;2(2):189-198. https://doi.org/10.1016/j.vhri.2013.06.009 [Links]

Omran D, Majumdar SR, Johnson JA, Tsuyuki RT, Lewanczuk RZ, Guirguis LM, Makowsky M, Simpson SH. Pharmacists on primary care teams: Effect on antihypertensive medication management in patients with type 2 diabetes. J Am Pharm Assoc (2003). 2015;55(3):265-268. https://doi.org/10.1331/japha.2015.14225 [Links]

Simpson SH, Lier DA, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, Spooner R, Johnson JA. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial. Diabet Med. 2015;32(7):899-906. https://doi.org/10.1111/dme.12692 [Links]

Pousinho S, Morgado M, Falcão A, Alves G. Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. J Manag Care Spec Pharm. 2016;22(5):493-515. https://doi.org/10.18553/jmcp.2016.22.5.493 [Links]

MacCallum L, Dolovich L. Follow-up in community pharmacy should be routine, not extraordinary. Can Pharm J (Ott). 2018;151(2):79-81. https://doi.org/10.1177/1715163518756586 [Links]

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853. https://doi.org/10.1016/S0140-6736(98)07019-6 [Links]

Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56) [published correction appears in Clin Sci (Lond) 2002 Jun;102(6):679]. Clin Sci (Lond). 2001;101(6):671-679. [Links]

Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847. https://doi.org/10.1161/01.cir.97.18.1837 [Links]

Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 1998;140(2):199-270. https://doi.org/10.1016/s0021-9150(98)90209-x [Links]

Gonzalez JS, Schneider HE, Wexler DJ, Psaros C, Delahanty LM, Cagliero E, Safren SA. Validity of medication adherence self-reports in adults with type 2 diabetes. Diabetes Care. 2013;36(4):831-837. https://doi.org/10.2337/dc12-0410 [Links]

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. https://doi.org/10.1056/nejmra050100 [Links]

Kheir NM, van Mil JW, Shaw JP, Sheridan JL. Health-related quality of life measurement in pharmaceutical care. Targeting an outcome that matters. Pharm World Sci. 2004;26(3):125-128. https://doi.org/10.1023/b:phar.0000026811.37414.4f [Links]

Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther. 1993;15(6):1121-1120. [Links]

David, Emmanuel A, Soremekun, Rebecca O, Abah, Isaac O, & Aderemi-Williams, Roseline I. (2021). Impact of pharmacist-led care on glycemic control of patients with uncontrolled type 2 diabetes: a randomized controlled trial in Nigeria. Pharmacy Practice (Granada) , 19 (3), 2402. Epub September 20, 2021. https://dx.doi.org/10.18549/pharmpract.2021.3.2402

Maduabuchi Romanus Ihekoronye, Kanayo Patrick Osemene, Theophilus Ehidiamen Oamen, Pharmacist-led intervention to improve treatment outcomes in type 2 diabetes: a randomized controlled trial, Journal of Pharmaceutical Health Services Research, Volume 15, Issue 2, June 2024, rmae005, https://doi.org/10.1093/jphsr/rmae005